Protocol Ledger

NCT07219459 · Phase II · RECRUITING

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

Interventional Phase II clinical trial protocol NCT07219459 sponsored by CatalYm in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-19 Enrollment: 104 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07219459
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)104 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07219459
Protocol FieldVerified Registry Value
NCT IdentifierNCT07219459
Consolidated Lead SponsorCatalYm
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment104 participants (ESTIMATED)
Registered Start Date2026-03-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI